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Significance of this study
What is already known about this subject?
 ► It has been established that sodium- glucose co- 
transporter-2 inhibitors (SGLT2i) are associated with 
greater risk for genital infections. However, patient 
features which confer the greatest risk are not well 
elucidated. Female gender is a known risk factor.
What are the new findings?
 ► Prior history of genital infection and gender are the 
two main determinants of risk of genital infection 
with SGLT2i.
 ► High HbA1c does not increase the risk of genital 
infection in those starting an SGLT2i, in contrast to 
those starting a DPP4 inhibitor.
 ► Genital infections are associated with only a slight 
increase in treatment discontinuation.
How might these results change the focus of 
research or clinical practice?
 ► These data can be used by clinicians to estimate the 
infection risk for individual patients and hence sup-
port more informed decision making.
AbStrAct
Introduction To identify risk factors, absolute risk, and 
impact on treatment discontinuation of genital infections 
with sodium- glucose co- transporter-2 inhibitors (SGLT2i).
Research design and methods We assessed the 
relationship between baseline characteristics and 
genital infection in 21 004 people with type 2 diabetes 
initiating SGLT2i and 55 471 controls initiating dipeptidyl 
peptidase-4 inhibitors (DPP4i) in a UK primary care 
database. We assessed absolute risk of infection in those 
with key risk factors and the association between early 
genital infection and treatment discontinuation.
Results Genital infection was substantially more common 
in those treated with SGLT2i (8.1% within 1 year) than 
DPP4i (1.8%). Key predictors of infection with SGLT2i were 
female sex (HR 3.64; 95% CI 3.23 to 4.11) and history of 
genital infection; <1 year before initiation (HR 4.38; 3.73 
to 5.13), 1–5 years (HR 3.04; 2.64 to 3.51), and >5 years 
(HR 1.79; 1.55 to 2.07). Baseline HbA1c was not associated 
with infection risk for SGLT2i, in contrast to DPP4i where 
risk increased with higher HbA1c. One- year absolute risk 
of genital infection with SGLT2i was highest for those with 
a history of prior infection (females 23.7%, males 12.1%), 
compared with those without (females 10.8%, males 
2.7%). Early genital infection was associated with a similar 
discontinuation risk for SGLT2i (HR 1.48; 1.21–1.80) and 
DPP4i (HR 1.58; 1.21–2.07).
Conclusions Female sex and history of prior infection 
are simple features that can identify subgroups at greatly 
increased risk of genital infections with SGLT2i therapy. 
These data can be used to risk- stratify patients. High HbA1c 
is not a risk factor for genital infections with SGLT2i.
InTRoduCTIon
Sodium- glucose co- transporter-2 inhibitors 
(SGLT2i) are an increasingly important oral 
medication class in type 2 diabetes1–3 with their 
use climbing dramatically in recent years.4–7 
They result in a broadly similar amount of 
glucose lowering compared with other oral 
agents but can also reduce blood pressure and 
result in modest weight loss.8–10 In addition 
to their glucose lowering effects, large- scale 
clinical trials have demonstrated reduction in 
cardiovascular and renal outcomes in high- 
risk groups with type 2 diabetes,11–13 as well as 
benefit in patients with heart failure whether 
or not they have type 2 diabetes.14 They can 
also be used as adjuvant therapy to insulin for 
the treatment of type 1 diabetes.15
SGLT2i reduce hyperglycemia in people 
with diabetes by increasing urinary excre-
tion of glucose.8 16 This induced glycosuria 
increases the risk of genital infections16 and 
both clinical trials and observational studies 
demonstrate a 2.5–6- fold increase in genital 
infections in people using SGLT2i compared 
with controls.10 16 17 A number of factors have 
been shown to be associated with risk of genital 
infection in the general population, in partic-
ular, female sex and diabetes, especially when 
glycemic control is poor.18 19 However, there 
has been limited investigation of the risk factors 
for genital tract infection in those initiating 
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SGLT2i therapy, or of the impact of infection on treatment 
discontinuation outside of a trial setting.
We aimed to determine the factors associated with the 
risk for developing a genital infection while on SGLT2i 
treatment and the impact of these infections on treatment 
discontinuation.
ReseaRCH desIgn and meTHods
We conducted a retrospective cohort analysis of people 
with type 2 diabetes initiating SGLT2i within a large 
population- based UK cohort; the UK Clinical Practice 
Research Datalink (CPRD). We examined the prevalence 
of genital infections during the first year of treatment. We 
explored the associations between baseline characteris-
tics and history of previous genital infections on infection 
risk during treatment and examined the impact of genital 
infections occurring early during treatment on subsequent 
medication discontinuation. For all analyses, we used 
people initiating dipeptidyl peptidase-4 inhibitors (DPP4i) 
as a comparison cohort. We used all available data up to the 
point of data extraction, July 2019.
setting and participants
CPRD is one of the larger longitudinal population- based 
medical records datasets in the world and provides a repre-
sentative sample of the UK population.20 People with type 2 
diabetes were identified using a method we have previously 
described in detail.21 In summary, they were identified 
using the presence of a diagnostic code for diabetes and 
the prescription of one or more glucose lowering medica-
tion(s). People were excluded if they had possible type 1 
diabetes or another diabetes type. Possible type 1 diabetes 
was defined as age of diagnosis less than 35 years, treatment 
with insulin therapy only, or initiation of insulin within 
1 year of diagnosis. Other forms of diabetes were excluded 
using the presence of indicative diagnostic codes including 
steroid- induced diabetes, gestational diabetes and mono-
genic diabetes.
The date of diabetes diagnosis was defined as the date 
of the first of: a diabetes diagnostic code, glucose lowering 
medication, or glycated hemoglobin (HbA1c)≥6.5% (48 
mmol/mol). Those who had a first diabetes indicator 
within 3 months of practice registration were excluded as 
their diagnosis date was uncertain and treatment history 
could not be determined.
From the cohort of people meeting our criteria for type 2 
diabetes with an identifiable date of diagnosis, we included 
everyone initiating SGLT2i (canagliflozin, dapagliflozin, 
and empagliflozin). This group then formed our main 
study cohort. We identified a comparison group of all 
people initiating DPP4i.
Participant baseline characteristics
We report the baseline clinical characteristics of both treat-
ment groups at medication initiation; age, sex, duration 
of diabetes, and body mass index (BMI), HbA1c, estimated 
glomerular filtration rate (eGFR), history of genital infec-
tions. BMI, HbA1c, and eGFR were defined using the most 
recent measurement within the 2 years prior to the drug 
start date. We excluded people with missing data for these 
baseline characteristics or with a baseline eGFR <45 mL/
min.
outcomes
A genital infection was defined as either a diagnosis code 
specific for a genital infection (eg, candida vaginitis or vulvo-
vaginitis in women, or balanitis, balanoposthitis in men), a 
prescription for antifungal therapy used specifically to treat 
genital infections (eg, an antifungal vaginal pessary), or a 
non- specific diagnosis of “thrush” with a topical antifungal 
prescribed on the same day. The timing of the most recent 
infection prior to the start of the index drug was used as 
a baseline variable and categorized as; occurring within a 
year, between 1 and 5 years, or longer than 5 years before 
start of the index drug.
Treatment discontinuation was defined as no repeat 
prescription issue of the index drug for 3 months (90 days). 
The discontinuation date was defined as 90 days after the 
date of the last prescription issue.
statistical methods
Associations between baseline characteristics and time 
to genital infection were assessed using Kaplan- Meier 
survival plots. We then performed multivariable Cox- 
regression analyses of time to genital infection separately 
for SGLT2i- treated and DPP4i- treated patients. Multivari-
able models were defined a priori to include age, sex, 
duration of diabetes, HbA1c prior to treatment, eGFR, 
BMI, and previous history of genital infections. People with 
incomplete follow- up were included and censored at loss 
to follow- up. Time to infection models was also censored 
at discontinuation of the medication of interest (SGLT2i 
or DPP4i). Drug additions or switching of background 
medications was ignored. Complete available follow- up 
data were used for the Cox models, that is, where follow- up 
beyond the first year of treatment was available, these data 
were also included in the models.
As a key baseline variable of interest, we also evaluated 
the non- linear association between HbA1c prior to drug 
initiation and subsequent risk for genital infection by fitting 
continuous baseline HbA1c as a restricted cubic spline with 
three knots, with adjustment for the same factors used in 
the multivariable models.
Based on the results of Cox regression models, we 
defined four important clinical risk groups using the two 
most discriminative baseline features: sex, and history of 
one or more genital infection. For each risk group, we 
report the proportion of people developing a genital infec-
tion during the first year of treatment. We also report the 
annual cumulative incidence of infection out to 4 years, in 
each risk group.
The impact of early infection on discontinuation was 
assessed using multivariable Cox- regression separately 
for SGLT2i- treated and DPP4i- treated patients. Multi-
variable models were adjusted for the same baseline vari-
ables included in the infection risk models: age, gender, 
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Table 1 The baseline characteristics of people initiated on 
an SGLT2i or DPP4i
SGLT2i 
(n=21 008)
DPP4i
(n=55 481)
Age (years) 60.4 (9.3) 63.3 (10.8)
Female (n (%)) 8115 (38.6) 22 274 (40.1)
Duration of diabetes (years) 9.1 (5.4) 7.9 (5.4)
  <5 years (n (%)) 6089 (29.0) 21 003 (37.9)
  5–10 years (n (%)) 7296 (34.7) 19 414 (35.0)
  >10 years (n (%)) 7623 (36.3) 15 064 (27.2)
Number of concurrent 
diabetes medications
1.7 (0.8) 1.4 (0.7)
HbA1c (% (mmol/mol)) 78.2 (16.7) 73.1 (16.6)
  <8.0 (<64)(n (%)) 4401 (20.9) 19 067 (34.4)
  8.0–9.5 (64–80) (n (%)) 8547 (40.7) 21 665 (39.0)
  >9.5 (>80) (n (%)) 8060 (38.4) 14 749 (26.6)
eGFR (mL/min) 87.9 (15.2) 82.7 (17.5)
  45–<60 mL/min (n (%)) 890 (4.2) 6997 (12.6)
  60–90 (n (%)) 9674 (46.0) 27 245 (49.1)
  >90 (n (%)) 10 444 (49.7) 21 239 (38.3)
BMI (kg/m2) 34.4 (6.7) 32.7 (6.6)
  <25 kg/m2 (n (%)) 946 (4.5) 5156 (9.3)
  25–30 kg/m2 (n (%)) 4747 (22.6) 16 040 (28.9)
  >30 kg/m2 (n (%)) 15 311 (72.9) 34 275 (61.8)
Previous genital mycosis (n (%))
  Never 16 877 (80.3) 46 663 (84.1)
  <1 year 722 (3.4) 1753 (3.2)
  1–5 years 1363 (6.5) 2943 (5.3)
  >5 years 2046 (9.7) 4122 (7.4)
Corticosteroid use (n (%)) 2317 (4.2) 718 (3.4)
Oestrogen use (n (%)) 665 (1.2) 252 (1.2)
Immunomodulator use (n 
(%))
629 (1.1) 219 (1.0)
All values shown are mean (SD) unless otherwise stated.
BMI, body mass index; DPP4i, Dipeptidyl peptidase-4 inhibitor; 
eGFR, estimated glomerular filtration rate; SGTL2, sodium- glucose 
co- transporter-2.
duration of diabetes, HbA1c prior to treatment, eGFR, BMI, 
and previous history of genital infections.
sensitivity analyses
Patient characteristics influence treatment selection and 
therefore potentially influence the results of our primary 
analysis. To explore this possibility further, we repeated the 
primary analysis in propensity score- matched subgroups. 
Matching by treatment choice (SGLT2i or DPP4i) was 
performed using a 1:1 matching ratio and a nearest 
neighbor matching algorithm (R MatchIt V3.0.2). Vari-
ables included in the propensity matching were: age, sex, 
duration of diabetes, number of concurrent medications, 
HbA1c prior to treatment, eGFR, BMI, and previous history 
of genital infections. We compared the baseline character-
istics between the SGLT2i and DPP4i matched groups using 
the χ² test for categorical variables and the unpaired t- test 
for continuous data. All reported p values are two- sided. 
We used these matched cohorts to replicate the primary 
analysis for genital infection risk. We also used them to 
examine the impact of treatment selection on genital infec-
tion rates overall and in our four clinical risk groups, that 
is, we compare the additional risk for infection incurred by 
treatment with an SGLT2i compared with a DPP4i.
Posthoc, we also performed two additional analysis. 
The first, a sensitivity analysis, explored the impact of 
removing genital infections identified using a combination 
of the non- specific diagnosis code “thrush” and a simulta-
neous topical treatment. This sensitivity analysis was only 
performed in females, as there was no condition specific 
treatment available (eg, antifungal pessaries) for males 
and as there were fewer diagnosis specific codes in males 
compared with females. The second explored associations 
between concurrent medications with potential associations 
with fungal infection: corticosteroids,22 oestrogen thera-
pies,23 24 and non- steroid immune- modulating medications 
.25 These were defined as being prescribed at baseline if a 
prescription was present in the clinical record within the 
3 months prior to initiation of the index drug. All oral 
corticosteroids were included for analysis; topical or other 
preparations were not considered. Oestrogen therapies 
comprised hormone replacement therapies, combined 
oral contraceptives, and topical vaginal oestrogen prepara-
tions. Immune- modulating medications comprised all non- 
steroid immunosuppressants listed in the British National 
Formulary including thiopurines (azathioprine and 
mercaptopurine), methotrexate, calcineurin inhibitors 
(tacrolimus and cyclosporine) and monoclonal antibodies.
ResulTs
Within CPRD, we identified 302 857 people who met our 
criteria for type 2 diabetes. Of these, 22 928 were initiated 
on an SGLT2i and 67 104 on a DPP4i. There was incom-
plete baseline data on HbA1c, eGFR, or BMI for 1920 
(8.4%) people initiating an SGLT2i and 11 623 (17.3%) 
initiating a DPP4i. There were some baseline differences 
between the remaining cohorts; those initiating SGLT2is 
were younger, had a higher male proportion, longer 
duration of diabetes, higher HbA1c, eGFR, and BMI, and 
more previous genital infections (table 1). The SGLT2i 
and DPP4i most commonly initiated were dapagliflozin 
and sitagliptin, respectively (online supplementary table 
S1).
Women and those with prior infection have higher genital 
infection risk
Genital infections were more common within the first 
year of treatment in those on SGLT2i (8.1%; 95% CI 
7.6% to 8.5%) compared with DPP4i (1.8%; 95% CI 
1.7% to 1.9%). Females were more likely to have a genital 
infection than males (figure 1A). Those with a history of 
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Figure 1 The proportion of people free from genital infection since drug initiation (A) by sex and medication class (SGLT2i and 
DPP4i) and (B) by history of prior genital infection and medication class. Number of events by group: (A) DPP4 inhibitor males 
n=228, DPP4 inhibitor females n=914, SGLT2i males n=371, SGLT2i females n=1092, (B) DPP4 inhibitor no prior infection 
n=484, DPP4 inhibitor and prior infection n=658, SGLT2i no prior infection n=729, SGLT2i and prior infection n=734. The 
shaded area represents the 95% CI. DPP4i, dipeptidyl peptidase-4 inhibitor; SGTL2i, sodium- glucoseco- transporter-2 inhibitor.
Table 2 Associations between patient characteristics at medication initiation and subsequent genital infections with SGLT2 
and DPP4 inhibitors
 
SGLT2i
(n=21 008)
HR (95% CI) P value
DPP4i
(n=55 481)
HR (95% CI) P value
Age (years) 0.99 (0.99 to 1.00) p=0.069 0.98 (0.98 to 0.99) p<0.001
Female 3.66 (3.24 to 4.13) p<0.001 4.05 (3.51 to 4.66) p<0.001
Duration of diabetes (Reference group: <5 years)
  5–10 years 0.87 (0.77 to 0.98) p=0.024 1.01 (0.89 to 1.14) p=0.91
  >10 years 0.93 (0.81 to 1.06) p=0.24 1.05 (0.91 to 1.22) p=0.49
HbA1c (Reference group:<8.0% (<64 mmol/mol))
  8.0%–9.5% (64–80 mmol/mol) 1.11 (0.97 to 1.27) p=0.13 1.12 (0.98 to 1.27) p=0.108
  >9.5% (>80 mmol/mol) 0.95 (0.83 to 1.09) p=0.49 1.48 (1.29 to 1.71) p<0.001
eGFR (Reference group:>90 mL/min)
  60–90 mL/min 0.78 (0.56 to 1.08) p=0.13 0.76 (0.61 to 0.96) p=0.019
  <60 mL/min 1.01 (0.90 to 1.13) p=0.87 0.96 (0.85 to 1.09) p=0.57
BMI (Reference group: 25–30 kg/m2)
  <25 kg/m2 0.78 (0.55 to 1.10) p=0.15 0.70 (0.53 to 0.93) p=0.016
  >30 kg/m2 1.22 (1.07 to 1.39) p=0.005 1.29 (1.13 to 1.48) p<0.001
Previous genital mycosis (Reference group: no previous infection)
  <1 year 4.47 (3.81 to 5.24) p<0.001 8.90 (7.67 to 10.34) p<0.001
  1–5 years 3.04 (2.64 to 3.51) p<0.001 4.13 (3.54 to 4.82) p<0.001
  >5 years 1.77 (1.53 to 2.04) p<0.001 2.00 (1.68 to 2.38) p<0.001
C- statistic 0.76 0.82
BMI, body mass index; DDP4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; HR, hazard ratio; SGTL2, sodium- glucose 
co- transporter-2.
previous genital infection were more likely to experience 
another infection after treatment initiation (figure 1B).
High Hba1c is not an additional risk factor for genital infection 
with sglT2is
In multivariable models, female gender, higher BMI, and 
genital infection were independently associated with risk 
for future genital infection in people treated with both 
SGLT2is and DPP4is (table 2). The more recent the 
previous genital infection, the greater the subsequent 
infection risk. Higher HbA1c was associated with greater 
infection risk in people using DPP4is but not SGLT2is 
(table 2 and figure 2). Sensitivity analysis using matched 
subgroups demonstrated the same pattern of association 
(online supplementary tables S2 and S3), as did analysis 
F
oundation T
rust. P
rotected by copyright.
 on O
ctober 20, 2020 at R
oyal D
evon and E
xeter N
H
S
http://drc.bm
j.com
/
B
M
J O
pen D
iab R
es C
are: first published as 10.1136/bm
jdrc-2020-001238 on 24 M
ay 2020. D
ow
nloaded from
 
5BMJ Open Diab Res Care 2020;8:e001238. doi:10.1136/bmjdrc-2020-001238
Emerging Technologies, Pharmacology and Therapeutics
Figure 2 The association between HbA1c prior to medication initiation and genital infection after initiation of (A) an SGLT2 
inhibitor and (B) a DPP4 inhibitor. Analyses are adjusted for age, gender, duration of diabetes, eGFR, BMI, and prior history of 
infection. The shaded area represents the 95% CI. A median HbA1c value of 8.6% (71mmol/mol) is used as the reference point. 
BMI, body mass index; DPP4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; SGTL2, sodium- 
glucoseco- transporter-2.
Figure 3 The absolute and relative risk of having a genital infection with an SGLT2i versus DPP4i by risk group. HRs are 
derived from propensity matched cohorts (online supplementary table S2) and are adjusted for age, gender, duration of 
diabetes, HbA1c, eGFR, BMI, and prior history of infection (online supplementary table S8). Numbers in brackets are 95% CIs. 
BMI, body mass index; DPP4i, dipeptidyl peptidase-4 inhibitor; eGFR, estimated glomerular filtration rate; HR, hazard ratio; 
SGTL2i, sodium- glucoseco- transporter-2 inhibitor.
excluding those with non- specific diagnosis codes (online 
supplementary table S4).
Including the use of oestrogens, corticosteroids, 
and other immune- modulating medications did not 
significantly modify the associations identified (online 
supplementary table S5). The use of these medications 
at treatment initiation was not associated with signifi-
cantly increased risk for infection in the SGLT2i group 
but corticosteroid and oestrogen use was associated with 
increased risk in those initiating DPP4is.
Future genital infection risk can be stratified using gender 
and infection history
Using the results of the regression models, we defined 
four key risk groups: males without a history of genital 
infection, males with a history of genital infection, 
females without a history of genital infection, females 
with a history of genital infection. These groups can be 
used to estimate the absolute risk for genital infection 
over the first year of treatment with an SGLT2i compared 
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with a DPP4i (figure 3 and online supplementary table 
S6) and over longer durations (online supplementary 
table S7) and the HR for infection associated with using 
an SGLT2i compared with a DPP4i (figure 3 and online 
supplementary table S8).
genital infections are associated with a greater risk of 
discontinuation
Genital infections occurring within the first month 
of treatment were associated with a greater adjusted 
risk for subsequent discontinuation with both SGLT2i 
(19.4% without discontinued versus 31.8% with by 1 year; 
adjusted HR 1.48; 95% CI 1.21 to 1.81) and DPP4i (19.0% 
without versus 36.4% with by 1 year; adjusted HR 1.58; 
95% CI 1.21 to 2.07).
ConClusIon
Our study shows sex and history of genital infection can 
be used to stratify the risk of genital infections over the 
first year of SGLT2i treatment. Absolute risk is markedly 
higher in those with prior infection (females 23.7%, 
males 12.1%), compared with those without (females 
10.8%, males 2.7%). In contrast, we found no evidence of 
an association between high HbA1c levels and increased 
risk of infection with SGLT2i, though we did for DPP4i. 
Early genital infection was associated with an increased 
discontinuation risk with SGLT2is (HR 1.48; 1.21 to 
1.80); this effect was also observed with DPP4is (HR 1.58; 
1.2 to 2.1).
Comparison with the literature
Our findings suggest that the prevalence of genital 
infections in clinical practice in people using SGLT2is is 
slightly higher overall (8.1%; 95% CI 7.6% to 8.5%) that 
that reported in large clinical trials with SGLT2is (2.5% 
to 6.5%).11–13 Despite the lower incidence in trials, meta- 
analyses of trial data show a 4–6- fold increased risk of 
genital infection with SGLT2i compared with placebo, 
consistent with our findings.10 26 Prior history of genital 
infection was also associated with a greater risk of further 
infection on SGLT2i treatment in clinical trials.16 This 
finding fits clinical experience.
The associations we identified between sex and prior 
history of infection are supported in a much smaller 
national audit of SGLT2i use from secondary care;27 
however, multivariable analysis was not performed in this 
study. A US claims- based study also found similar sex asso-
ciations.28 Our data provide the first estimates of abso-
lute and relative genital infection risk with SGLT2i across 
clinical groups defined using simple patient characteris-
tics. To our knowledge, no previous study has explored 
the independent association between HbA1c and genital 
infection with SGLT2i, analyzed over a wide range of 
HbA1c values and this is a critical and novel finding. We 
also provide the first simple clinical stratification tool to 
estimate genital infection risk across four key risk groups.
strengths and limitations
Important strengths of our analysis are the large cohort 
size, high levels of data completeness in the diabetes 
cohort from which our sample was derived and the real- 
world nature of the data. These factors mean our results 
have broad generalizability and can be applied to current 
clinical practice. There are some noteworthy limitations. 
Our analysis relies, in part, on correct clinical coding of 
genital infections and is therefore subject to inaccuracies 
resulting from non- coding or miscoding of genital infec-
tions. However, the rates of genital infections in our anal-
ysis are consistent with other smaller studies which used 
case note review to identify genital infections and therefore 
not subject to coding errors.29 30 Topical antifungal treat-
ments are available to purchase ‘over- the- counter’ and 
therefore some people may have treated their genital infec-
tions without presenting to primary care; we therefore may 
have systematically under recorded infection rates. The 
severity of infections was not available; for example, para-
phimosis and other complication data were not sufficiently 
well recorded to analyze these outcomes. An additional 
limitation is that data on the reasons for treatment discon-
tinuation were not available for this study.
Clinical implications
We provide the first simple clinical method for stratifying 
risk for genital infections with SGLT2i across four key risk 
groups; both absolute risks and HRs compared with DPP4i. 
This can be used in clinical practice to support patients to 
make more informed treatment selection decisions. If those 
at highest risk elect to start an SGLT2i, then practitioners 
should pay particular attention to counseling regarding 
genital hygiene and when to start antifungal treatments. 
While early infection was associated with a greater chance 
of discontinuation, this effect was also seen with DPP4i. 
Other recent work has demonstrated that simple clinical 
features can be used to stratify risk of side- effects with sulfo-
nylurea and thiazolidinedione treatment.31 32 Along this, 
our findings provide a starting point for a more personal-
ized approach to selecting type 2 diabetes treatment after 
metformin, with specific medication targeted according to 
individuals or subgroups based on their biological or risk 
characteristics.33
Interestingly, we found that people with high HbA1c are 
not at additional genital infection risk with SGLT2i. This 
may be because glycosuria is a universal feature of SGLT2i 
treatment, occurring even in people with a normal HbA1c.
34 
It is therefore plausible that the association between glycos-
uria and genital infection reaches a saturation point above 
which increased glycosuria does not increase infection 
risk. This threshold may be exceeded with SGLTi use even 
in those with a relatively low HbA1c. By contrast, in those 
on DPP4i treatment, the amount of glycosuria will be low 
in those with the lowest serum glucose and will progres-
sively increase with higher HbA1c as the serum glucose 
progresses past the renal threshold of maximum glucose 
resorption.35 It is similarly interesting that corticosteroids, 
immune- modulating medications, and oestrogen therapies 
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were not associated with significant additional infection 
risk in those using SGLT2i. The reasons for this are unclear. 
While we are likely to be underpowered (particularly with 
immune- modulating therapies) to detect small increases in 
risk, our data reassuringly suggest no substantial increase in 
risk if these treatments are used concurrently with SGLT2i.
In conclusion, genital infections are common in people 
on SGLT2i in clinical practice. Major risk factors of infec-
tion are female sex and prior infection but not baseline 
HbA1c, meaning risk can be stratified by these two simple 
clinical features.
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